Literature DB >> 25497318

Dry powder inhalers: physicochemical and aerosolization properties of several size-fractions of a promising alterative carrier, freeze-dried mannitol.

Waseem Kaialy1, Ali Nokhodchi2.   

Abstract

The purpose of this work was to evaluate the physicochemical and inhalation characteristics of different size fractions of a promising carrier, i.e., freeze-dried mannitol (FDM). FDM was prepared and sieved into four size fractions. FDMs were then characterized in terms of micromeritic, solid-state and bulk properties. Dry powder inhaler (DPI) formulations were prepared using salbutamol sulphate (SS) and then evaluated in terms of drug content homogeneity and in vitro aerosolization performance. The results showed that the crystalline state of mannitol was maintained following freeze-drying for all size fractions of FDM. All FDM particles showed elongated morphology and contained mixtures of α-, β- and δ-mannitol. In comparison to small FDM particles, FDMs with larger particle sizes demonstrated narrower size distributions, higher bulk and tap densities, lower porosities and better flowability. Regardless of particle size, all FDMs generated a significantly higher (2.2-2.9-fold increase) fine particle fraction (FPF, 37.5 ± 0.9%-48.6 ± 2.8%) of SS in comparison to commercial mannitol. The FPFs of SS were related to the shape descriptors of FDM particles; however, FPFs did not prove quantitative apparent relationships with either particle size or powder bulk descriptors. Large FDM particles were more favourable than smaller particles because they produced DPI formulations with better flowability, better drug content homogeneity, lower amounts of the drug depositing on the throat and contained lower fine-particle-mannitol. Optimized stable DPI formulations with superior physicochemical and pharmaceutical properties can be achieved using larger particles of freeze-dried mannitol (FDM).
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dry powder inhaler; Fine particle fraction; Freeze-dried mannitol; Homogeneity; Overall desirability; Particle size

Mesh:

Substances:

Year:  2014        PMID: 25497318     DOI: 10.1016/j.ejps.2014.12.005

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  6 in total

Review 1.  Physical stability of dry powder inhaler formulations.

Authors:  Nivedita Shetty; David Cipolla; Heejun Park; Qi Tony Zhou
Journal:  Expert Opin Drug Deliv       Date:  2019-12-13       Impact factor: 6.648

2.  Nanocomposite microparticles (nCmP) for the delivery of tacrolimus in the treatment of pulmonary arterial hypertension.

Authors:  Zimeng Wang; Julie L Cuddigan; Sweta K Gupta; Samantha A Meenach
Journal:  Int J Pharm       Date:  2016-08-26       Impact factor: 5.875

3.  Synthesis and Characterization of Nanocomposite Microparticles (nCmP) for the Treatment of Cystic Fibrosis-Related Infections.

Authors:  Zimeng Wang; Samantha A Meenach
Journal:  Pharm Res       Date:  2016-04-18       Impact factor: 4.200

4.  Formulating Inhalable Dry Powders Using Two-Fluid and Three-Fluid Nozzle Spray Drying.

Authors:  Donglei Leng; Kaushik Thanki; Camilla Foged; Mingshi Yang
Journal:  Pharm Res       Date:  2018-11-01       Impact factor: 4.200

Review 5.  Influence of physical properties of carrier on the performance of dry powder inhalers.

Authors:  Tingting Peng; Shiqi Lin; Boyi Niu; Xinyi Wang; Ying Huang; Xuejuan Zhang; Ge Li; Xin Pan; Chuanbin Wu
Journal:  Acta Pharm Sin B       Date:  2016-05-04       Impact factor: 11.413

Review 6.  Imagine the Superiority of Dry Powder Inhalers from Carrier Engineering.

Authors:  Piyush Mehta
Journal:  J Drug Deliv       Date:  2018-01-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.